GLP-1 Weight Loss Injections in San Diego: What to Actually Expect Beyond the Hype
The conversation around GLP-1 medications has moved faster than the medical establishment's ability to talk about them honestly. In the last two years, semaglutide and tirzepatide have gone from prescription drugs known mostly to endocrinologists to subjects of magazine covers, dinner-party debates, and Hollywood whisper networks. The headlines have produced a flood of patients walking into clinics across San Diego asking for "the shot" — often without a clear sense of what these medications actually are, who they are appropriate for, and what the experience of taking them is genuinely like.
At Skin Haven, GLP-1 weight loss injections have become one of the most-requested services we offer. They are also one of the most misunderstood. What follows is an attempt to talk about them the way we talk about them with patients in consultation: candidly, with respect for the science, and with clear-eyed attention to both their genuine power and the realities of what they ask of the people taking them.
What GLP-1 medications actually are
Glucagon-like peptide-1 (GLP-1) is a hormone your body produces naturally in the gut after you eat. It does several things at once: signals your pancreas to release insulin, slows the rate at which your stomach empties, and communicates to your brain that you are satisfied. People with type 2 diabetes often produce less of it, which is why the first GLP-1 medications were developed for diabetes management.
What clinicians and patients began noticing, almost immediately, was that the same medications were producing significant, sustained weight loss in patients who took them — including patients without diabetes. The mechanism turned out to be straightforward: by mimicking the body's natural satiety signal, these medications dramatically reduce appetite, particularly for the high-calorie, hyper-palatable foods that dominate the modern diet.
Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the two GLP-1 medications most commonly prescribed for weight management in 2026. They work in similar ways with one important distinction: tirzepatide also activates a second receptor (GIP), which appears to make it modestly more effective for weight loss in head-to-head clinical trials.
The results — what the data actually shows
Clinical trials of GLP-1 medications for weight management consistently produce results of a magnitude not previously seen with any non-surgical intervention.
Semaglutide trial participants lost, on average, 15% of their body weight over 68 weeks. Tirzepatide participants lost, on average, 21% of their body weight over a similar period — at the highest dose, more than 25%. For comparison: diet and exercise interventions typically produce 3–5% weight loss that is rarely sustained beyond two years.
These are not, in our experience, marketing numbers. The results in our practice mirror the trial data closely. Patients who follow the protocol consistently — and who pair the medication with the lifestyle scaffolding the medication makes finally accessible — see meaningful, sustained results.
The medication is not magic. It is, however, the first pharmaceutical intervention in the history of weight management that genuinely changes the underlying physiology, rather than asking patients to white-knuckle their way against it.
Who is appropriate for GLP-1 treatment
The honest answer is: not everyone who asks. We turn down GLP-1 candidates more often than people expect.
Appropriate candidates typically include patients with a BMI of 30 or above, or a BMI of 27 or above with a weight-related health condition (high blood pressure, prediabetes, sleep apnea, joint pain, polycystic ovary syndrome, or insulin resistance). These are the FDA-approved indications, and we adhere to them with care.
We are particularly thoughtful about prescribing for patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, or active pancreatitis. These are absolute contraindications. We are also cautious with patients who have a history of disordered eating; the medication's appetite-suppressing effect can be either therapeutic or harmful in this population, depending on context, and the conversation requires real care.
We do not prescribe GLP-1 medications for cosmetic weight loss in patients who are at a healthy BMI and want to lose "just a few pounds for an event." This is not a use case the medications were designed for, the cost-to-benefit calculation does not favor it, and we believe the practice of prescribing in this way contributes to the broader cultural distortion the headlines have created.
What the experience of treatment actually feels like
Patients who begin GLP-1 treatment and have the most positive experience tend to share two things: they are at peace with starting at a low dose, and they are honest with themselves about side effects.
The first month typically brings a meaningful reduction in appetite, often within the first week. Many patients describe a quiet shift — the constant background hum of food thoughts simply softens. The "food noise" that drove a lifetime of grazing, snacking, and second helpings becomes much quieter. Patients report eating half their normal portion at dinner and not finishing it. They report walking past the kitchen at night without stopping. The change is more psychological than mechanical.
Side effects are real and worth taking seriously. Nausea is the most common, particularly in the first two weeks of each dose increase. Constipation is nearly universal at some point in the protocol; we have a hydration and fiber strategy we walk patients through. Fatigue, occasional reflux, and changes in taste are common. A small subset of patients experience more significant gastrointestinal side effects that warrant slowing the titration or discontinuing the medication. We monitor closely.
The dose escalates over months, not weeks. A typical semaglutide protocol starts at 0.25 mg weekly and increases gradually to a target dose (commonly 1.0 mg or 2.4 mg) over four to five months. Tirzepatide follows a similar pattern. This pacing matters: patients who push for faster escalation experience worse side effects with no improvement in long-term results.
Weight loss is steady, not dramatic. Most patients lose one to two pounds per week in the first two months, then settle into a slower one to one-and-a-half pounds per week. The trajectory is reliable, but it is not the rapid drop that some social media accounts portray. Patients who expect overnight transformation are disappointed; patients who commit to twelve months are usually thrilled.
What we insist on, alongside the medication
The medication does the metabolic work. The patient does the lifestyle work. Both are required.
Protein matters more on GLP-1 than off it. Reduced overall food intake makes it surprisingly easy to undereat protein, which accelerates muscle loss alongside fat loss. We coach patients toward a target of 0.8 to 1.0 grams of protein per pound of goal body weight, every day, without fail.
Resistance training is non-negotiable. Without strength training, a meaningful percentage of the weight lost on GLP-1 medications is muscle, not fat. With strength training (two to three sessions per week, even modestly), patients preserve lean mass and produce a body composition change that's dramatically better than a scale-only loss.
Hydration is essential. Reduced eating means reduced incidental water from food. Patients who don't compensate often experience the side effects (constipation, fatigue, headache) more sharply than those who do. We frequently pair GLP-1 patients with our IV hydration service in the first eight weeks for this reason.
B12 and iron supplementation are often appropriate. Reduced appetite can produce nutritional gaps within months. We screen for these proactively and supplement (often with our injectable B12 protocol) when indicated.
The cost question, asked plainly
GLP-1 medications are expensive. Brand-name semaglutide and tirzepatide can run $1,000 to $1,400 per month without insurance coverage. Compounded versions — produced by licensed compounding pharmacies — are significantly less, often $250 to $450 per month, and have become the predominant form of treatment in medical practices across the country.
The compounded medication conversation is its own subject and is worth having in person. Compounding is a legitimate, regulated practice, and the medications produced by reputable compounding pharmacies are formulated with the same active ingredient as the brand-name versions. Compounding has also been the subject of FDA scrutiny and pharmaceutical industry pushback. We use only U.S.-licensed, 503A-compliant compounding pharmacies and we test the supply we receive. The conversation about which form of medication is right for any individual patient is one we take seriously.
The exit strategy
Almost no one talks about this part. Patients on GLP-1 medications eventually want to know: do I have to be on this forever?
The honest answer, based on what the research shows so far: most patients who stop the medication regain a significant percentage of the lost weight within one to two years. The medication is changing your physiology while you take it; when you stop, the physiology returns to baseline.
This is not a failure of the medication; it is its mechanism. The patients in our practice who have most successfully maintained their results after discontinuing have done so by using the time on the medication to build durable lifestyle systems — strength training they actually enjoy, food preferences that have genuinely shifted, sleep and stress practices that have become habits — that survive the absence of pharmaceutical support.
For some patients, the right answer is long-term low-dose maintenance. For others, the right answer is structured discontinuation with intensive lifestyle support. For others, the medication was a tool that did its work and is no longer needed. The right answer is a conversation, not a protocol.
What a Skin Haven consultation looks like
A first GLP-1 consultation at Skin Haven runs about 45 minutes. We review your full medical history, recent labs (or order them if appropriate), medications, and the broader context of your health and weight history. We talk about what success looks like for you, what side effects you can realistically manage, and what lifestyle scaffolding you have or need to build. We do not prescribe in the first appointment for any patient who is not clearly an appropriate candidate.
If you are appropriate, we begin at the lowest standard dose, schedule monthly check-ins, and adjust as your body tells us how to. We coordinate with your primary care provider when relevant. We remain reachable between appointments for the side-effect questions that always arise in week two of a new dose.
This is not a service we approach lightly. The medications are powerful. They deserve practitioners who treat them as such.
Considering GLP-1 weight loss treatment in San Diego? Book a consultation at Skin Haven for an honest, thorough conversation about whether it's the right approach for you.
Editorial & Medical Disclaimer
The content published on the Skin Haven journal is intended for informational and educational purposes only. It is not intended as, and should not be construed as, medical advice, diagnosis, or treatment. Reading this content does not establish a provider-patient relationship between you and Skin Haven Aesthetics & Wellness or any of its practitioners.
Aesthetic and wellness treatments — including injectables, biostimulators, microneedling, chemical peels, IV therapy, NAD+ therapy, weight loss medications, and PRP — carry inherent risks and may not be appropriate for every patient. Individual results vary based on genetics, skin condition, medical history, lifestyle, adherence to aftercare, and other factors. Any decision to pursue treatment should be made in consultation with a qualified, licensed healthcare provider after a thorough evaluation of your individual medical history, current medications, and treatment goals.
Skin Haven Aesthetics & Wellness operates in compliance with applicable California law, including the California Business and Professions Code, the regulations of the Medical Board of California, and the regulations of the Board of Registered Nursing. All medical aesthetic services involving prescription medications, injectables, or procedures regulated as the practice of medicine are performed by or under the supervision of Dr. Ronald Chao, MD, our supervising physician, in accordance with California's standardized procedures and good-faith examination requirements.
Statements regarding treatment outcomes, durations, and protocols reflect general clinical experience and published research; they are not guarantees of any specific result. Treatment timelines referenced in this content (for example, "results visible at 12 weeks") describe typical ranges observed in clinical practice, not promises applicable to any individual patient.
Brand names referenced in this content — including but not limited to Botox®, Dysport®, Daxxify®, Xeomin®, Sculptra®, Restylane®, Juvederm®, RHA®, Belotero®, Ozempic®, Wegovy®, Rybelsus®, Mounjaro®, and Zepbound® — are the registered trademarks of their respective manufacturers. References to these products are made for educational and comparative purposes and do not imply endorsement, sponsorship, or affiliation between those manufacturers and Skin Haven Aesthetics & Wellness.
If you are experiencing a medical emergency, call 911 or seek immediate care from a qualified emergency provider. For non-emergency questions about a treatment you have received or are considering, please contact Skin Haven directly or consult your primary care provider.
© Skin Haven Aesthetics & Wellness. All content is the property of Skin Haven and may not be reproduced without permission.
